Integrated BioSci Research On Atara Biotherapeutics: What’s Next After CAR-T? – Seeking Alpha
Seeking Alpha |
Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR–T?
Seeking Alpha The approval of Yescarta proved that CAR-T (based on CD4 T cells) works. Atara uses a similar mechanism of action and targets the CAR-T (that leverages on CD8). Data for ATA-129 for EBV franchise is robust. Phase 1 results for the MS franchise is also … |
